2021-01-11,"Jaguar Health Exploring Possibility of Conditional Marketing Authorization for Proposed Inflammatory Diarrhea Indication for Crofelemer, Initially in Long-Hauler COVID-19 Recovery Patients in Europe"
2021-01-08,Why Jaguar Health Stock Skyrocketed 49% Today
2021-01-06,"Jaguar Health Subsidiary Receiving Preclinical Services from the National Institute of Allergy and Infectious Diseases for New Preclinical Study Initiated January 6, 2021 for Lechlemer Plant-Based Drug Candidate for the Symptomatic Relief of Diarrhea from Cholera"
2021-01-05,"Jaguar Health shares soar  40% in heavy volume, on track for 18-month high"
2021-01-05,Return On Capital Employed Overview: Jaguar Health
2020-12-28,5 Value Stocks In The Healthcare Sector
2020-12-24,"Company News for Dec 24, 2020"
2020-12-23,4 Hot Penny Stocks Trading Under $1 That Need To Be On Your Watchlist
2020-12-23,Jaguar Health Signs Second Agreement for $6 Million Non-dilutive Financing Transaction Involving the Sale of Royalty Rights Related to Future Mytesi (Crofelemer) and Lechlemer Revenue Stream
2020-12-22,Jaguar Health Reports Voting Results from Special Meeting of Stockholders & Announces December 23rd Investor Webinar
2020-12-15,"REMINDER: Jaguar Health to Host Investor Call Thursday, December 17, 2020 to Allow Management to Review Developments Since the Definitive Proxy Statement for the Companys December 9, 2020 Special Meeting of Stockholders Was Filed"
2020-12-10,"Jaguar Health Announces Adjournment of Its Special Meeting of Stockholders Until Tuesday, December 22, 2020"
2020-12-07,"Nasdaq's Listing and Hearing Review Council Stays Panel Determination Requiring Jaguar Health's Compliance with the Bid Price Requirement by December 23, 2020"
2020-12-04,"Jaguar Health and its Subsidiary, Napo Pharmaceuticals, Enter into Fifth Amendment to the Accounts Receivable Purchase Agreement with Oasis Capital, LLC, Dated May 12, 2020"
2020-12-01,Return On Capital Employed Overview: Jaguar Health
2020-11-30,A Look Into Healthcare Sector Value Stocks
2020-11-30,"Jaguar Health Announces Plan to Develop and Commercialize Crofelemer, the Company's Novel Proprietary Drug, for the Indication of Inflammatory Diarrhea, Initially in 'Long-Hauler' COVID-19 Recovery Patients"
2020-11-24,Jaguar Health Announces Release of Podcast Interview with The Wall Street Resource
2020-11-16,"Jaguar Health, Inc. Reports 2020 Third Quarter Financial Results"
2020-11-10,"Jaguar Health to Host Investor Call Monday, November 16th at 8:30 a.m. Eastern Regarding Q3 2020 Financials & Business Updates"
2020-10-29,Jaguar Health Receives Positive Nasdaq Listing Determination
2020-10-21,Jaguar Health CEO And Lead Ethnobotanical Researcher Explain The Decades Of Research That Made It A Leader In Plant-Based Drug Treatment
2020-10-20,"Reminder: Jaguar Health Hosting Exclusive Virtual Educational Event, ""Diarrhea Dialogues: Why Bowel Control is Critical to Supportive Care in Cancer"""
2020-10-16,Jaguar Health Announces New Employee Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
2020-10-15,"Napo Pharmaceuticals, a Subsidiary of Jaguar Health, Launches Web-based NapoCares Platform to Enhance Patient Access to Mytesi"
2020-10-15,Jaguar Health CEO Discusses Upcoming Virtual Event Highlighting Long-Term Treatment Needs Of Cancer Patients
2020-10-14,"Jaguar Health and Its Subsidiary Bolster Management Team with Appointment of Melissa Yeager, J.D. as Senior Vice President, Regulatory Affairs & Quality Assurance"
2020-10-13,Jaguar Health Provides Updates Regarding Company Capitalization Strategy
2020-10-12,Overview Of Value Stocks In The Healthcare Sector
2020-10-07,Jaguar Health Subsidiary Napo Pharmaceuticals Initiates Pivotal Phase 3 Clinical Trial of Crofelemer (Mytesi) for Prophylaxis of Diarrhea in Adult Cancer Patients Receiving Targeted Cancer Therapy
2020-10-06,Jaguar Health Meets Financial Condition for Sale of Royalty Rights for Mytesi (Crofelemer) Indications
2020-10-02,Jaguar Health's Mental Health Entheogen Therapeutics Initiative Targets Plant-based Candidate Compound for Possible Schizophrenia and Psychoses Indications
2020-10-01,"Jaguar Health Signs Agreement for Non-dilutive Financing Transaction Involving the Sale of Royalty Rights Related to Future Mytesi (Crofelemer) Revenue Stream for $5 Million, with Possible Future Tranches in 2021, Totaling $16 Million"
2020-09-28,Jaguar Health Subsidiary Napo Pharmaceuticals Sponsoring 2020 National Trans Visibility March
2020-09-24,Jaguar Health to Host Exclusive Virtual Educational Event Diarrhea Dialogues: Why Bowel Control is Critical to Supportive Care in Cancer
2020-09-21,A Look Into Healthcare Sector Value Stocks
2020-09-16,Jaguar Health Establishes World-Class Scientific Strategy Team to Support Newly Launched Mental Health Entheogen Therapeutics Initiative
2020-09-11,Jaguar Health to Present at Virtual H.C. Wainwright 22nd Annual Global Investment Conference September 16
2020-09-10,"Jaguar Health and its Subsidiary, Napo Pharmaceuticals, Enter into Third Amendment to the Accounts Receivable Purchase Agreement with Oasis Capital, LLC, Dated May 12, 2020"
2020-09-07,How Much is Jaguar Health's (NASDAQ:JAGX) CEO Getting Paid?
2020-09-03,"Jaguar Launches Mental Health Entheogen Therapeutics Initiative to Develop Novel, Natural Prescription Medicines Derived from Psychoactive Plants"
2020-09-02,"Jaguar Health Completes Transactions that Increase Stockholders' Equity Above $5,000,000"
2020-08-19,Jaguar Health Provides Updates on Investigator-Initiated Trials of Crofelemer (Mytesi)
2020-08-18,Jaguar Health Submits Final Regulatory Filing for Approval of Canalevia (Crofelemer) to Treat Chemotherapy-induced Diarrhea in Dogs
2020-08-14,"Jaguar Health and its Subsidiary, Napo Pharmaceuticals, Enter into a Second Amendment to the Accounts Receivable Purchase Agreement with Oasis Capital, LLC, Dated May 12, 2020"
2020-08-13,"Jaguar Health, Inc. Reports 2020 Second Quarter Financial Results"
2020-08-11,Jaguar Health to Host Investor Call August 13th at 8:30 a.m. Eastern Regarding Q2 2020 Financials and Business Updates
2020-08-06,Jaguar Health Announces Activation of Investigational New Drug (IND) for Crofelemer (Mytesi) for Prophylaxis and Symptomatic Relief of Cancer TherapyRelated Diarrhea
2020-08-03,5 Value Stocks In The Healthcare Sector
2020-07-22,Jaguar Health Announces New Employee Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
2020-07-22,"Jaguar Health Subsidiary Receiving Preclinical Services from the National Institute of Allergy and Infectious Diseases for New Preclinical Study Initiated July 21, 2020 for Lechlemer Plant-based Drug Candidate for Cholera"
2020-07-21,"Jaguar Health Reports Voting Results from July 21, 2020 Special Meeting of Stockholders"
2020-07-20,FDA Invites Jaguar Health to Expedite Submission of Regulatory Filing for Approval of Canalevia (Crofelemer) to Treat Chemotherapy-induced Diarrhea in Dogs
2020-07-06,Jaguar Health Subsidiary Napo Pharmaceuticals Completes Filing of Investigational New Drug Application for Crofelemer (Mytesi) for Symptomatic Relief of Cancer TherapyRelated Diarrhea
2020-07-02,Jaguar Health Submits Final Major Regulatory Filing for Approval of Canalevia (Crofelemer) to Treat Exercise-induced Diarrhea in Dogs
2020-06-29,"Jaguar Health and its Subsidiary, Napo Pharmaceuticals, Enter an Amendment to the Accounts Receivable Purchase Agreement with Oasis Capital, LLC, Dated May 12, 2020"
2020-06-25,Bet on 4 Stocks With Rising P/E to Beat Market Blues
2020-06-23,Jaguar Health Announces New Employee Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
2020-06-23,Preclinical Study Demonstrating Symptomatic Relief of Diarrhea in Dogs Receiving Neratinib in Combination with Crofelemer (Mytesi) Presented at American Association for Cancer Research Virtual Annual Meeting
2020-06-22,"On World Rainforest Day, Jaguar Health Reinforces Commitment to Amazon Rainforest and Sustainable Harvesting Programs for Plant-based Pharmaceuticals"
2020-06-19,Jaguar Health Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2020-06-10,Edited Transcript of JAGX earnings conference call or presentation 15-May-20 12:30pm GMT
2020-06-03,Edited Transcript of JAGX earnings conference call or presentation 6-Apr-20 12:30pm GMT
2020-05-28,Jaguar Health Submits Final Major Regulatory Filing for Approval of Canalevia (Crofelemer) to Treat Chemotherapy-induced Diarrhea in Dogs
2020-05-26,Jaguar Health Sustainability Leader Interviewed on Foodie Pharmacology Podcast
2020-05-22,Jaguar Health Announces Exercise of Warrants for $4.45 Million Gross Proceeds
2020-05-20,Jaguar Health Pursuing Contracting Opportunities with Insurers to Improve Patient Access for Company's Non-opioid Plant-Based Mytesi Drug Product
2020-05-15,"Jaguar Health Reports Voting Results from May 15, 2020 Annual Meeting of Stockholders"
2020-05-15,"Jaguar Health, Inc. Reports 2020 First Quarter Financial Results"
2020-05-13,"Jaguar Health and its Subsidiary, Napo Pharmaceuticals, Enter Accounts Receivable Purchase Agreement with Oasis Capital, LLC"
2020-05-12,Jaguar Health to Host Investor Call May 15th at 8:30 a.m. Eastern Regarding Q1 2020 Financials & Business Updates
2020-05-12,Jaguar Health Clears Important Hurdle on Path to Approval of Canalevia (Crofelemer) to Treat Exercise-Induced Diarrhea (EID) in Dogs
2020-05-03,Pricing of Covid-19 Products Will Face Public Scrutiny
2020-04-16,"Jaguar Health Enters Deal with Atlas Sciences to Develop NP-500, a Jaguar Non-Core Plant-based Type II Diabetes Drug Candidate"
2020-04-06,Jaguar Health Reports 2019 Financial Results and Business Updates
2020-04-03,Jaguar Health to Host Investor Call April 6th at 8:30 a.m. Eastern Regarding Q4 2019 Financials & Business Updates
2020-04-02,Napo Pharmaceuticals Expands Mytesi (Crofelemer) Patient Support Program
2020-04-01,Jaguar Health Clears Key Regulatory Hurdle on Path to Approval of Canalevia (Crofelemer) to Treat Chemotherapy-Induced Diarrhea in Dogs
2020-03-12,"Jaguar Health Subsidiary Napo Pharmaceuticals to Host Facebook Live ""HIV Community Conversation"" Event with HIV Advocate Alleen King-Carter March 13, 2020 at 3 p.m. Eastern"
2020-03-09,The Jaguar Health (NASDAQ:JAGX) Share Price Is Down 95% So Some Shareholders Are Very Salty
2020-03-05,Jaguar Health Secures Non-dilutive Capital Through Sale of Royalty Rights Related to Future Mytesi Revenue Stream
2020-02-20,Jaguar Health Subsidiary Napo Pharmaceuticals Wins 2019 Varro E. Tyler Commercial Investment in Phytomedicinal Research Award
2020-02-06,"Jaguar Health Subsidiary Napo Pharmaceuticals to Host Facebook Live ""HIV Community Conversation"" Event with HIV Advocate Davina Otalor February 7, 2020 at 3 p.m. Eastern"
2020-01-08,Jaguar Health Announces that Published Study Indicates Crofelemer Could be a Treatment Option for Abdominal Pain Associated with Diarrhea-Predominant Irritable Bowel Syndrome
2020-01-07,"One Thing To Remember About The Jaguar Health, Inc. (NASDAQ:JAGX) Share Price"
2019-12-16,Jaguar Health Announces Study to Evaluate the Safety and Effectiveness of Crofelemer for Treatment of Chronic Idiopathic Diarrhea in Non-HIV Patients
2019-12-10,"Jaguar Health Subsidiary Napo Pharmaceuticals to Host HIV Activism Digital Summit December 13, 2019 at 3 p.m. Eastern"
2019-11-21,"Jaguar Health Subsidiary Napo Pharmaceuticals to Host Facebook Live ""HIV Community Conversation"" Event with Transgender Advocate Yonce Jones November 22, 2019 at 3 p.m. Eastern"
2019-11-20,Article About Jaguar Health Published in Fall 2019 Issue of MicroCap Review Magazine
2019-11-20,MicroCap Review Magazine Fall 2019 Issue Now Available
2019-11-14,"Jaguar Health, Inc. Reports 2019 Third Quarter Financial Results"
2019-11-14,Jaguar Health Announces that Interim Analysis Requirement Met in Phase 2 HALT-D Study Evaluating Mytesi (Crofelemer) for Prevention and Prophylaxis of Diarrhea in Breast Cancer Patients
2019-11-13,"Jaguar Health Appoints Ian Wendt Vice President, Commercial Strategy"
2019-11-12,"Jaguar Health to Host Investor Call Nov. 14th at 9 a.m. Eastern Regarding Interim Analysis of HALT-D Study of Mytesi (Crofelemer) for Prevention of Diarrhea in Breast Cancer Patients, Q3 Financials & Business Updates"
2019-11-05,14 Low Float Stocks With High Short Interest
2019-10-30,"Jaguar Health Subsidiary Napo Pharmaceuticals Enters ex-U.S. Distribution Agreement for Mytesi (Crofelemer) with TannerGAP, Inc."
2019-10-23,"Jaguar Health Announces Completion of Preclinical Studies of Lechlemer, the Company's Human Drug Product Candidate for Cholera and Acute Infectious Diarrhea"
2019-10-22,Jaguar Health's Study Shows Mytesi (Crofelemer) May Support Treatment of Diarrhea in Cancer Patients Receiving Targeted Therapy While Also Enabling Maintenance and Tolerability of a Higher Dose of the Selected TKI
2019-10-18,These 24 Bay Area drug and diagnostics companies quietly raised nearly $3B this year
2019-10-15,"MicroCap Rodeo Investor Conference Lineup for October 15 and 16, 2019"
